MedTrace Logo

Oral Propionate to Treat and Prevent Diabetes

NCT01692002 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-06-18

Study results available
· View outcomes & findings →

Summary

The aim of these studies is to firstly determine the pharmacokinetic profile of orally administered enteric coated sodium propionate. Subsequently, the most efficacious dose at improving glucose tolerance following an oral glucose challenge will be determined. The investigators will then determine the mechanism of action of propionate, whether it acts by altering beta cell function directly or by augmenting the incretin effect or both

Conditions

Interventions

DIETARY_SUPPLEMENT

Sodium propionate

Sodium propionate capsule or tablet

DIETARY_SUPPLEMENT

Sodium Chloride

Placebo capsule or tablet

PROCEDURE

Oral glucose tolerance test

PROCEDURE

Intravenous glucose tolerance test.

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Gavin A Bewick, PhD. · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2019-08-31
Completion
2019-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01692002 on ClinicalTrials.gov